⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Official Title: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Study ID: NCT04227522

Interventions

Rucaparib
Placebos

Study Description

Brief Summary: MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary in first line therapy.

Detailed Description: The main scope of this trial is to determine progression free survival in BRCA negative patients treated with Rucaparib as maintenance therapy vs. Placebo after receiving Bevacizumab for 12 to 15 months. BRCA negative patients will be stratified according to time point of surgery (adjuvant vs. neoadjuvant), result of surgery (tumor free vs. not tumor free resection), study site and response (complete response (CR) vs. partial response (PR)/SD) and randomized 2:1 to receive either Rucaparib (Arm A) or Placebo (Arm B). In both of the arms, tumor assessments (CT or MRI) are performed before randomization, and every 6 months thereafter. During treatment, clinical visits (blood cell counts, detection of toxicity) occur every 4 weeks. Physical examinations will take place every 12 weeks. Safety will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs). About 30 sites in Germany will participate in this study to recruit 190 BRCA negative patientsin 24 months.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Universitätsklinikum Aachen, Aachen, , Germany

ANregiomed Frauenklinik Ansbach, Ansbach, , Germany

Helios Klinikum Berlin-Buch, Berlin, , Germany

CharitÊ - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, , Germany

Universitätsklinikum Bonn, Bonn, , Germany

Städtisches Klinikum Dessau, Dessau, , Germany

Universitätsklinikum Carl Gustav Carus, Dresden, , Germany

Kliniken Essen Mitte, Essen, , Germany

Universitätsklinikum Hamburg-Eppendorf, Hamburg, , Germany

ViDia Christliche Kliniken Karlsruhe Vincentius-Diakonissen-Kliniken g AG, Karlsruhe, , Germany

Städtisches Krankenhaus Kiel, Kiel, , Germany

ZAGO-Zentrum fßr ambulante gynäkologische Onkologie, Krefeld, , Germany

Universitätsklinikum Mannheim, Mannheim, , Germany

LMU Klinikum Großhadern, München, , Germany

Universitätsklinikum Mßnster, Mßnster, , Germany

CaritasKlinikum SaarbrĂźcken, SaarbrĂźcken, , Germany

Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, , Germany

Contact Details

Name: Jalid Sehouli, Prof. Dr.

Affiliation: CharitÊ - Universitätsmedizin Berlin, Campus Virchow Klinikum

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: